Biotech
Commented by Armin Schulz on September 4th, 2026 | 07:35 CEST
From the Pill to the Dissolving Film and the Monthly Injection for Obesity: Novo Nordisk, BioNxt Solutions and Pfizer
Obesity treatment is undergoing a transformation. Following the initial success of GLP-1 medications, the next round is now underway. It is no longer just about efficacy, but also about the method of administration. Novo Nordisk was the first to launch the oral pill on the European market and is already testing lower maintenance doses. BioNxt Solutions is countering with oral dissolvable thin films (ODFs) that require neither a needle nor water. Pfizer, meanwhile, is focusing on a monthly ultra-long-acting GLP-1 derived through its acquisition of Metsera. Today we take a closer look at the strategies of Novo Nordisk, BioNxt Solutions and Pfizer.
Read
Commented by Fabian Lorenz on September 1st, 2026 | 07:45 CEST
Potential Moderna-Style Share Surge? Takeover Candidates Evotec, Valneva and Vidac Pharma in Focus — Analysts Bullish
Moderna has shaken up the biotech market with its breakthrough in the fight against skin cancer. Partner Merck has received somewhat less attention in the coverage, despite preparing for the eventual patent expiration of one of its blockbuster drugs. Other pharmaceutical companies will also need to replenish their pipelines in the coming years. As a result, the takeover merry-go-round is likely to pick up speed again, potentially electrifying investors. One hot candidate is Vidac Pharma. Recruitment for its Phase 2B trial into high-risk actinic keratosis, a precancerous skin condition, has been completed. The results could provide a catalyst for the stock. Valneva's share price has recently risen sharply. Could its partner Pfizer eventually make a move? Analysts are recommending the stock. And what about perennial takeover candidate Evotec? Shareholders and potential buyers are currently giving the share a wide berth. Yet there is a "Buy" recommendation on the table.
Read
Commented by Matthias Schomber on August 31st, 2026 | 06:55 CEST
Market Opportunities and Contrasts: Novo Nordisk with Weight-Loss Pill, ASIC Concerns at DroneShield, Power Metallic Mines with Breakout Potential
Danish pharmaceutical giant Novo Nordisk has suffered a significant setback in the fierce race for the lucrative weight-loss drug market, but its new weight-loss pill could now prove to be a game changer. At the same time, Australian drone specialist DroneShield is facing regulatory headwinds that are severely testing investor confidence, yet the numbers remain strong. Away from these companies, Canada's resource sector has another standout in Power Metallic Mines, which is demonstrating impressively how a solid polymetallic discovery and excellent drilling results can inject strength and momentum into a stock chart performance. Read on to find out why these three stocks deserve a place on every watchlist right now!
Read
Commented by Fabian Lorenz on August 31st, 2026 | 06:45 CEST
Shock at BioNTech! Insider Buying at Nordex! Comeback Story for dynaCERT!
Could dynaCERT become the comeback story of the year? Analysts at GBC Research certainly believe the cleantech stock could rise to EUR 0.48. The shares are currently trading at EUR 0.06. The company's German management team is working hard to engineer a comeback. In particular, it has recently celebrated successes in commercializing its technology in Vietnam and Mexico. Further positive news should follow in the coming months. BioNTech, on the other hand, shocked its shareholders with Friday's announcement. The Phase 2 trial of its cancer immunotherapy candidate for colorectal cancer has been halted. Does this mean the mRNA race against Moderna is lost? The Nordex share has also recently lost momentum. The stock has been moving sideways since February. But now an insider purchase is attracting attention. Not all analysts, however, share the optimism.
Read
Commented by Lars Winter on August 26th, 2026 | 07:20 CEST
Money, Money, Money: RE Royalties, Aumann and Pfizer Put Dividend Investors in the Money
Dividends are far more than just a consolation prize during weak market phases. Profit distributions typically account for a large portion of a stock's total return. In addition, dividends generally fluctuate much less than earnings and share prices. A high yield alone, however, is not a seal of quality. It can also result from a sharp drop in the share price, an overextended payout ratio, or an impending cut. Many dividend enthusiasts therefore also seek reliability. The three selected dividend stocks cover different strategies: RE Royalties entices with a double-digit yield and the greatest upside potential, but also carries the highest risk. Aumann, on the other hand, is a short-term speculative play offering a generous special dividend, largely financed by its well-stocked cash reserves. Pfizer, in contrast, offers the lowest yield of the trio but boasts the longest and most reliable dividend history. We take a closer look at these stocks.
Read
Commented by André Will-Laudien on August 25th, 2026 | 09:15 CEST
Biotech M&A Boom: Novo Nordisk & Eli Lilly Battle for Market Share — BioNxt and Evotec on the Radar
As the recent spectacular USD 43 billion acquisition of cancer specialist Seagen by Pfizer and the mega-deals surrounding the GLP-1 infrastructure impressively demonstrate, the pharmaceutical industry is in the midst of a historic wave of consolidation. Driven by the massive, billion-dollar profits from the weight-loss injection market, an unprecedented wave of acquisitions has now begun. Market leaders such as Novo Nordisk and Eli Lilly are using their well-stocked war chests to pursue strategic mega-acquisitions to secure their dominant positions and systematically eliminate production bottlenecks. At the same time, highly innovative platform companies like BioNxt are coming into focus with their novel delivery systems. Strategically valuable targets currently trading at attractive valuations, such as Evotec, have long been in the crosshairs of investors and competitors. Those who do not want to be left behind in the battle for market share, new delivery technologies, and the next generation of blockbuster drugs must make acquisitions now, because the M&A carousel is spinning faster than it has in a long time. We dig a little deeper!
Read
Commented by Matthias Schomber on August 25th, 2026 | 06:40 CEST
Evotec, Palantir, dynaCERT: 3 Stocks, 3 Stories — Which One Could Deliver the Best Returns?
Palantir, Evotec and dynaCERT are three companies from different industries. The US-based AI specialist is celebrating a 93% revenue increase and making short sellers bleed. The Hamburg-based biotech group Evotec, on the other hand, is mired in crisis, operating at a loss, and struggling to turn things around through cost-cutting measures. And then there is dynaCERT, which, with its patented hydrogen technology, does not aim to reinvent the diesel engine, but could very well revolutionize it. Which stock could perform the best, and which ones are worth a closer look? Where will boldness be rewarded? We take a closer look for you.
Read
Commented by Matthias Schomber on August 24th, 2026 | 08:20 CEST
Cancer Breakthrough and Defense Boom: BioNTech and Moderna Take Off! Can Volatus Aerospace Follow Suit?
In the capital markets, two entirely different future-oriented industries are simultaneously stepping into the spotlight. While in the biotech sector, hopes for groundbreaking cancer therapies are fueling a massive comeback for companies such as Moderna and BioNTech, a highly exciting turnaround candidate may be emerging in the specialized field of unmanned aviation. Investors are rightly asking themselves whether the recent optimism surrounding biotech stocks is underpinned by fundamental strength or whether it is merely a short-lived flash in the pan followed by a sell-off. Those who can now read the right signals in financial data and chart patterns may be able to identify which stocks are poised for the next major trend movements. We take a closer look for you.
Read
Commented by Stefan Feulner on August 24th, 2026 | 07:50 CEST
Merck, Vidac Pharma, Moderna: New Cancer Treatments Send Stock Markets Soaring
A breakthrough in cancer research sent the stock market into a frenzy last week. For the first time, a personalized mRNA therapy has achieved key endpoints in a large Phase 3 trial, adding billions in market value within hours. At the same time, smaller biotech companies are working on entirely different approaches to target tumors at one of their greatest vulnerabilities. The race for the next generation of cancer treatments is thus gaining momentum. The economic potential is enormous.
Read
Commented by Fabian Lorenz on August 24th, 2026 | 07:45 CEST
Sell Rheinmetall? Evotec with AI Potential and Lahontan Gold's 22% Resource Boost!
Should investors sell Rheinmetall shares? That is the recommendation from mwb research. The analysts continue to view Rheinmetall as a clear operational winner in the European defense boom. However, they believe market expectations starting in 2028 are too ambitious. The company's order backlog is not as robust as many assume. By contrast, there are strong arguments for a rising share price at Lahontan Gold. The gold price climbed back above USD 4,600, suggesting that a new rally in the precious metal could be getting underway—the perfect timing to give the Lahontan story a boost. The company plans to build a mine and begin gold production next year. Most recently, the resource estimate was raised by 22%. And what about Evotec? Its stock is at rock bottom. Can AI-driven optimism provide new momentum?
Read